In the latest trading session, 2.87 million Moderna Inc (NASDAQ:MRNA) shares changed hands as the company’s beta touched 1.84. With the company’s most recent per share price at $33.55 changed hands at -$1.98 or -5.57% at last look, the market valuation stands at $12.91B. MRNA’s current price is a discount, trading about -408.11% off its 52-week high of $170.47. The share price had its 52-week low at $29.25, which suggests the last value was 12.82% up since then.
Analysts gave the Moderna Inc (MRNA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.82. If we narrow down to specifics, the data shows that 2 out of 17 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 3 recommended MRNA as a Hold, 12 felt it is a Buy and 0 rated the stock as Underweight. Moderna Inc’s EPS for the current quarter is expected to be -3.14.
Moderna Inc (NASDAQ:MRNA) trade information
Instantly MRNA was in red as seen in intraday trades today. With action 1.70%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -19.31%, with the 5-day performance at 1.70% in the green. However, in the 30-day time frame, Moderna Inc (NASDAQ:MRNA) is -20.85% down.
The consensus price target for the stock as assigned by Wall Street analysts is 63.5, meaning bulls need an upside of 47.17% from its recent market value. According to analyst projections, MRNA’s forecast low is 45 with 238 as the target high. To hit the forecast high, the stock’s price needs a -609.39% plunge from its current level, while the stock would need to soar -34.13% for it to hit the projected low.
Moderna Inc (MRNA) estimates and forecasts
Year-over-year growth is forecast to reach -33.86% down from the last financial year.
Consensus estimates given by 10 financial analysts project the company’s revenue in the current quarter to hit an average of 134.46M. 10 analysts are of the opinion that Moderna Inc’s revenue for the current quarter will be 121.45M. The company’s revenue for the corresponding quarters a year ago was 167M and 241M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -19.48%. The estimates for the next quarter sales put growth at -49.61%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -42.94%. The 2025 estimates are for Moderna Inc earnings to decrease by -5.85%, but the outlook for the next 5-year period is at 14.97% per year.
Moderna Inc (NASDAQ:MRNA)’s Major holders
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 10.3568% or 39.56 million shares worth $4.7 billion as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and Vanguard 500 Index Fund. With 11.0 shares estimated at $371.06 million under it, the former controlled 2.86% of total outstanding shares. On the other hand, Vanguard 500 Index Fund held about 2.30% of the shares, roughly 8.86 shares worth around $298.89 million.
